NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
DR. Reddy’s Laboratories Limited RDY
10 fiscal years on record · INR · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
INR 325.5B
▲ 16.6% vs FY2023
EPS · FY24
INR 67.78
Dividend / sh · FY24
INR 40.00
Payout · FY24
12%
ROE · FY24
18.4%
Net margin · FY24
17.4%
Dividend coverage
1.7×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
INR 325.5B
Revenue, FY2024 · full 10-year series below
Revenue
Net income
17 cents of every revenue dollar became profit this year.
Per share
INR 67.78
Diluted EPS, FY2024
EPS
Dividend
Earnings covered the dividend 1.7 times — the rest stayed in the company.
Profitability
18.4%
Return on equity, FY2024
ROE
Operating margin22.1%
Net margin17.4%
Return on assets12.8%
Each INR of equity produced 18 cents of profit this year.
Returned to shareholders
INR 8.1B
returned in FY2024 · dividends + net buybacks
Dividends paidINR 6.7B
Net buybacksINR 1.4B
Share of profit14.2%
Consecutive raises—
INR 6.7B in dividends and INR 1.4B in buybacks — 14% of the year's profit went back to shareholders.
Growth
+13.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+14.9%
+13.3%
Net income
+33.9%
+23.7%
Returned to shareholders
+24.8%
+12.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.83B
Shares outstanding, FY2024
Change, 5 years−2.9%
Change, 10 years—
The share count shrank 3% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
INR 493.0B
total assets, end of FY2024
Total assetsINR 493.0B
EquityINR 333.4B
CashINR 14.7B
Gross debtINR 8.7B
Net debtINR -5.9B
Current ratio1.92×
The company holds more cash than debt.
History
10 fiscal years
Every figure from documents filed with the SEC · INR
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue INR B
325.5
279.2
245.9
214.4
189.7
174.6
153.9
142.0
140.8
154.7
Operating income INR B
71.8
67.7
57.1
29.5
24.3
16.0
20.9
11.9
13.5
29.6
EBITDA INR B
·
·
·
·
·
·
·
23.6
24.8
39.9
Income tax INR B
19.5
16.2
15.3
8.7
9.2
−1.5
3.6
4.5
2.6
7.1
Net income INR B
56.5
55.7
45.1
23.6
17.2
19.5
18.8
9.8
12.0
20.0
EPS, diluted INR
67.78
66.80
54.17
141.69
103.65
117.40
113.09
59.00
72.09
116.98
Dividend / sh INR
40.00
40.00
30.00
25.00
25.00
20.00
20.00
20.00
20.00
20.00
Payout %
12
12
11
18
24
20
21
41
28
21
ROE %
18.4
19.8
·
·
·
·
·
·
·
·
Shares out B
0.83
0.83
0.83
0.17
0.17
0.17
0.17
0.17
0.17
0.17
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
38 of 38
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed